The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rate
Open accessAbstract
BACKGROUND AND PURPOSE: BAF312 is a next‐generation sphingosine 1‐phosphate (S1P) receptor modulator, selective for S1P 1 and S1P 5 receptors. S1P 1 receptors are essential for lymphocyte egress from lymph nodes and a drug target in immune‐mediated diseases. Here, we have characterized the immunomodulatory potential of BAF312 and the S1P receptor‐mediated effects on heart rate using preclinical and human data. EXPERIMENTAL APPROACH: BAF312 was tested in a rat experimental autoimmune encephalomyelitis (EAE) model. Electrophysiological recordings of G‐protein‐coupled inwardly rectifying potassium (GIRK) channels were carried out in human atrial myocytes. A Phase I multiple‐dose trial studied the pharmacokinetics, pharmacodynamics and safety of BAF312 in 48 healthy subjects. KEY RESULTS: BAF312 effectively suppressed EAE in rats by internalizing S1P 1 receptors, rendering them insensitive to the egress signal from lymph nodes. In healthy volunteers, BAF312 caused preferential decreases in CD4+ T cells, T naïve, T central memory and B cells within 4–6 h. Cell counts returned to normal ranges within a week after stopping treatment, in line with the elimination half‐life of BAF312. Despite sparing S1P 3 receptors (associated with bradycardia in mice), BAF312 induced rapid, transient (day 1 only) bradycardia in humans. BAF312‐mediated activation of GIRK channels in human atrial myocytes can fully explain the bradycardia. CONCLUSION AND IMPLICATIONS: This study illustrates species‐specific differences in S1P receptor specificity for first‐dose cardiac effects. Based on its profound but rapidly reversible inhibition of lymphocyte trafficking, BAF312 may have potential as a treatment for immune‐mediated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Sphingosine-1-phosphate: an enigmatic signalling lipid
Spiegel, S., & Milstien, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1103 · Cited by 2,075
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947 · cited 2×
“…which has shown nanomolar affinity as an agonist at four of the five S1P receptors (S1P1, S1P3, S1P4 and S1P5; receptor nomenclature follows Alexander et al., 2011) and acts as a functional antagonist at S1P1 receptors, inducing receptor internalization and rendering T and B cells…”
BackgroundGuidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Self-citationChemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs
Cyster, J. G. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115628 · Cited by 856 · cited 3×
“The preclinical efficacy of BAF312 in the EAE model can, to a large extent, be explained by reduced recirculation of autoreactive lymphocytes and prevention of their infiltration into the CNS (Fujino et al., 2003; Balatoni et al., 2007).”
BackgroundMethodSanna, M. G., Liao, J., Jo, E., Alfonso, C., Ahn, M.-Y., Peterson, M. S., Webb, B., Lefebvre, S., Chun, J., Gray, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311743200 · Cited by 626
Self-citationBrinkmann, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.006 · Cited by 528
Self-citationHeterogeneity of CD4+ memory T cells: Functional modules for tailored immunity
Sallusto, F., & Lanzavecchia, A. (2009) · European Journal of Immunology · doi:10.1002/eji.200939722 · Cited by 348
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
Mehling, M., Brinkmann, V., Antel, J., Bar-Or, A., Goebels, N., Vedrine, C., Kristofic, C., Kuhle, J., Lindberg, R. L. P., & Kappos, L. (2008) · Neurology · doi:10.1212/01.wnl.0000327609.57688.ea · Cited by 345
Self-citationForrest, M., Sun, S.-Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062828 · Cited by 333
Jolly, P. S., Bektas, M., Olivera, A., Gonzalez-Espinosa, C., Proia, R. L., Rivera, J., Milstien, S., & Spiegel, S. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030680 · Cited by 319
Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X.-K. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 280
Adelmann, M., Wood, J., Benzel, I., Fiori, P., Lassmann, H., Matthieu, J.-M., Gardinier, M. V., Dornmair, K., & Linington, C. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00124-7 · Cited by 232
Engagement of S1P1-degradative mechanisms leads to vascular leak in mice
Oo, M. L., Chang, S.-H., Thangada, S., Wu, M.-T., Rezaul, K., Blaho, V., Hwang, S.-I., Han, D. K., & Hla, T. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45403 · Cited by 216
Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules
Marsolais, D., & Rosen, H. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2356 · Cited by 167
Koyrakh, L., Roman, M. I., Brinkmann, V., & Wickman, K. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00754.x · Cited by 166
Self-citationBalatoni, B., Storch, M. K., Swoboda, E.-M., Schönborn, V., Koziel, A., Lambrou, G. N., Hiestand, P. C., Weissert, R., & Foster, C. A. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.06.023 · Cited by 158
Insights into the pharmacological relevance of lysophospholipid receptors
Mutoh, T., Rivera, R. R., & Chun, J. J. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01622.x · Cited by 150
Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors
Müllershausen, F., Craveiro, L. M., Shin, Y., Cortés-Cros, M., Bassilana, F., Osinde, M., Wishart, W. L., Guerini, D., Thallmair, M., Schwab, M. E., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04629.x · Cited by 142
Self-citationLorentzen, J. C., Issazadeh‐Navikas, S., Storch, M. K., Mustafa, M., Lassman, H., Linington, C., Klareskog, L., & Olsson, T. P. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00153-0 · Cited by 138
Gonzalez‐Cabrera, P. J., Jo, E., Sanna, M., Brown, S. J., Leaf, N. B., Marsolais, D., Schaeffer, M., Chapman, J. V., Cameron, M. D., Guerrero, M., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049783 · Cited by 129
Pan, S., Mi, Y., Pally, C., Beerli, C., Chen, A. P., Guerini, D., Hinterding, K., Nuesslein‐Hildesheim, B., Tuntland, T., Lefebvre, S., et al. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.017 · Cited by 129
Self-citationSphingosine-1-phosphate signaling in the cardiovascular system
Peters, S. L. M., & Alewijnse, A. E. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.09.008 · Cited by 125
Piali, L., Froidevaux, S., Hess, P., Nayler, O., Bolli, M. H., Schlosser, E., Kohl, C., Steiner, B., & Clozel, M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176487 · Cited by 110
Effective Half‐Life in Clinical Pharmacology
Boxenbaum, H., & Battle, M. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04117.x · Cited by 106 · cited 3×
“Effective elimination half-life based on drug accumulation at steady-state (Boxenbaum and Battle, 1995).”
BackgroundInfluentialActivation of muscarinic K+ current in guinea‐pig atrial myocytes by sphingosine‐1‐phosphate.
Bünemann, M., Brandts, B., zu Heringdorf, D. M., van Koppen, C. J., Jakobs, K. H., & Pott, L. (1995) · The Journal of Physiology · doi:10.1113/jphysiol.1995.sp021084 · Cited by 104
Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate
Roviezzo, F., Del Galdo, F., Abbate, G., Bucci, M., D'Agostino, B., Antunes, E., De Dominicis, G., Parente, L., Rossi, F., Cirino, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401439101 · Cited by 100 · cited 2×
“, 2008), human eosinophil chemotaxis and selective in vivo recruitment (Roviezzo et al., 2004), as well as mast cell degranulation and chemotaxis (Jolly et al.”
BackgroundBaumruker, T., Billich, A., & Brinkmann, V. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.283 · Cited by 94
Self-citationGollmann, G., Neuwirt, H., Tripp, C. H., Mueller, H., Konwalinka, G., Heufler, C., Romani, N., & Tiefenthaler, M. (2008) · International Immunology · doi:10.1093/intimm/dxn050 · Cited by 55
Drug-Induced Lymphopenia: Focus on CD4+ and CD8+ Cells
Gergely, P. A. (1999) · Drug Safety · doi:10.2165/00002018-199921020-00003 · Cited by 47
Self-citation
Cited by
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Sphingolipid metabolites in inflammatory disease
Maceyka, M., & Spiegel, S. (2014) · Nature · doi:10.1038/nature13475 · Cited by 1,277
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Self-citationTargeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Kunkel, G. T., Maceyka, M., Milstien, S., & Spiegel, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4099 · Cited by 434
Groves, A., Kihara, Y., & Chun, J. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.02.011 · Cited by 314
Metadata
- Authors
- Gergely, P., Nuesslein‐Hildesheim, B., Guerini, D., Brinkmann, V, Traebert, M., Bruns, C., Pan, S., Gray, N., Hinterding, K., Cooke, N., Groenewegen, A., Vitaliti, A., Sing, T., Luttringer, O., Yang, J., Gardin, A., Wang, N., Crumb Jr, W., Saltzman, M., Rosenberg, M., & Wallström, E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-10-08
- Volume
- 167
- Issue
- 5
- Pages
- 1035-1047
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1493585689
- Cited by
- 305
- References
- 35
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.